These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33119175)

  • 1. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    Winn AN; Keating NL; Dusetzina SB
    J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Shen C; Zhao B; Liu L; Shih YT
    Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
    Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
    Kenzik KM; Bhatia R; Williams GR; Bhatia S
    Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia.
    Darkow T; Maclean R; Joyce GF; Goldman D; Lakdawalla DN
    Am J Manag Care; 2012 Nov; 18(11 Suppl):S272-8. PubMed ID: 23327459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
    Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
    Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
    Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
    Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
    Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
    Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
    Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
    J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
    Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
    Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
    Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
    Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
    Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.